Moderna's Road To Stopping The Red - Seeking Alpha

17 hours ago · Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my analysis of MRNA stock.

80%
OFF

Moderna's Road To Stopping The Red - Seeking Alpha

2 weeks from now

17 hours ago · Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my analysis of MRNA stock.

seekingalpha.com

$1
OFF

Moderna’s Strategic Revision And Pipeline Potential: A Buy Rating ...

2 weeks from now

Sep 13, 2024 · In a report released today, Gena Wang from Barclays maintained a Buy rating on Moderna (MRNA – Research Report), with a price target of $1...

businessinsider.com

34%
OFF

1 Green Flag For Moderna In 2022, And 1 Red Flag

2 weeks from now

Dec 4, 2021 · The past two years have been incredible for Moderna (MRNA-7.34%)-- and its investors.Shares of the biotech company surged more than 430% in 2020. And they're …

fool.com

46%
OFF

Moderna Enters Green After Six Straight Sessions In Red

2 weeks from now

Sep 26, 2024 · Moderna (NASDAQ:MRNA) shares snapped six straight sessions of losses, as the stock closed 0.46% higher at $63.93 on Thursday.The Massachusetts-based pharmaceutical …

seekingalpha.com

03%
OFF

Moderna Stock Traded In The Red For Seven Straight Days

2 weeks from now

Jun 14, 2024 · Moderna shares traded in the red on Friday, making it the seventh straight day of losses.The stock is down 4.03% at $139.38. MRNA has risen 8.91% in the last 12 months and …

seekingalpha.com

FAQs about Moderna's Road To Stopping The Red - Seeking Alpha Coupon?

Why did Moderna cut R&D?

Moderna's decision to cut R&D by $1.1 billion signals reduced confidence in its Covid business and/or its pipeline. The company's Covid vaccine revenue is declining, and concerns about mRNA technology may further dampen demand for its future shots. ...

Why did Moderna reduce its R&D activities?

Moderna, Inc.'s (NASDAQ: MRNA) decision to significantly reduce the scope of its R&D activities shows a lack of confidence in its Covid business and/or its pipeline and will meaningfully lower the number of "shots on goal" that it has going forward. Meanwhile, its Covid vaccine business is contracting rapidly amid significant challenges. ...

Will Moderna reduce its R&D budget in 2027?

On Sept. 12, Moderna disclosed that it would reduce its R&D budget by about $1.1 billion between 2024 and 2027. Specifically, the firm's R&D outlays are slated to drop to $3.6 billion to $3.8 billion in 2027 from $4.8 billion this year. As a result of the change, the vaccine maker is dropping five of the programs in its pipeline. ...

Can Moderna become a 250 billion+ market cap company?

I do see potential for Moderna to become a 250 billion+ market cap company given their progress with cancer vaccines and other viruses. The mRNA platform they have is tough to beat, and I like that they're collaborating with OpenAI as well. It's been a painful few years though as a shareholder... ...

Why is Moderna's mRNA stock unattractive?

The company's Covid vaccine revenue is declining, and concerns about mRNA technology may further dampen demand for its future shots. Despite potential first-mover advantage with a combined Covid/flu vaccine, significant competition for the latter shot and Moderna's high valuation make MRNA stock unattractive. ...

Why did Moderna (mRNA) stock crash Thursday?

"The company and its partner Merck will continue engaging with regulators on the program and remain focused on executing the Phase 3 trial," it said. However, Moderna (MRNA) shares tanked Thursday as the company announced plans to cut its annual R&D budget by $1.1B starting in 2027. ...